Parathyroid Adenoma Detection With Rubidium-82 Imaging
PARAGON
1 other identifier
observational
20
1 country
2
Brief Summary
Assess the uptake of rubidium-82 in parathyroid adenomas.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Nov 2025
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 25, 2025
CompletedFirst Posted
Study publicly available on registry
August 1, 2025
CompletedStudy Start
First participant enrolled
November 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2028
August 22, 2025
August 1, 2025
1.8 years
July 25, 2025
August 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Uptake pattern of rubidium-82 in parathyroid adenomas
Rudibium-82 uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.
3 months
Secondary Outcomes (1)
Comparison between the uptakes of rubidium-82 and 18F-fluorocholine in patients with parathyroid adenomas
3 months
Interventions
PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.
Eligibility Criteria
20 participants with a diagnosis of primary parathyroid adenoma who have previously undergone 18F-fluorocholine imaging will be recruited.
You may qualify if:
- Age ≥ 18y
- Ability to undergo imaging logistics
- Ability to provide informed consent
- Biochemical evidence of primary hyperparathyroidism
- Documented parathyroid adenoma on prior 18F-fluorocholine imaging
You may not qualify if:
- Normocalcemic primary hyperparathyroidism
- Breastfeeding or pregnancy
- Claustrophobia or inability to undergo imaging logistics
- Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Montreal Heart Institute
Montreal, Quebec, H1T 1C8, Canada
Montreal Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Pelletier-Galarneau
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Chief of the Nuclear Medicine Department
Study Record Dates
First Submitted
July 25, 2025
First Posted
August 1, 2025
Study Start
November 1, 2025
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
September 1, 2028
Last Updated
August 22, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share